On January 28, 2026, the FDA cleared the first IND (Investigational New Drug) application for a cellular rejuvenation therapy based on partial epigenetic reprogramming. The candidate is called ER-100. It is developed by Life Biosciences, a Boston-based company co-founded by David Sinclair, professor of genetics at Harvard Medical School (source).
This clearance marks a milestone. Not because it guarantees efficacy — a Phase 1 trial only measures safety — but because it represents the transition of a fundamental laboratory concept into regulated clinical evaluation. Partial epigenetic reprogramming leaves the realm of speculation and enters the domain of proof.
To understand the significance of this step, we need to go back twenty years.
From Yamanaka to Partial Reprogramming: Twenty Years of Maturation
In 2006, Shinya Yamanaka and Kazutoshi Takahashi demonstrated that four transcription factors (proteins that control gene activation) were sufficient to reprogram a specialized adult cell into a pluripotent stem cell, one capable of becoming any cell type. These four factors — OCT4, SOX2, KLF4, and c-MYC, collectively designated "OSKM" — erased the epigenetic marks (the chemical modifications that dictate which genes are active in each cell) accumulated during cell specialization and returned the cell to an embryonic state (PubMed).
The discovery earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012. But complete reprogramming posed a fundamental problem for therapeutic applications. A fully reprogrammed cell loses its identity: a neuron becomes an undifferentiated stem cell, a cardiomyocyte likewise. In vivo, this total dedifferentiation produces teratomas — chaotic tumors containing various tissue types (bone, skin, teeth). The c-MYC factor compounded the risk, being itself a potent proto-oncogene (a gene capable of promoting tumor growth when overactivated).
The question that emerged in the following years was logical: can a cell be rejuvenated without being completely dedifferentiated? Can the epigenetic clock be reset without erasing cellular identity?
The answer began to take shape in 2016 with the work of Juan Carlos Izpisua Belmonte at the Salk Institute. His team showed that brief, cyclic expression of OSKM factors in progeroid mice (genetically programmed for accelerated aging) improved several aging markers and extended lifespan without causing tumors. The key lay in temporal dosage: too-long activation led to dangerous dedifferentiation, while brief and cyclic activation rejuvenated cells while preserving their function (PubMed).
It was in this context that a strategic choice was made by several laboratories. Rather than using all four OSKM factors, they removed c-MYC from the cocktail. The remaining trio — OCT4, SOX2, KLF4, designated "OSK" — retains partial reprogramming capacity while considerably reducing oncogenic risk.
Lu et al. 2020: Restoring Vision in Mice
The major preclinical turning point came in December 2020, with the publication in Nature of work by Yuancheng Lu, Benedikt Brommer, and David Sinclair. This study demonstrated three converging results in mice (PubMed).
First result: following optic nerve crush injury, introduction of OSK factors into cells via an AAV2 vector (a harmless virus modified to serve as a genetic delivery vehicle) enabled regeneration of the axons (nerve extensions) of retinal ganglion cells, the retinal neurons that transmit visual information to the brain. These cells, under normal conditions, do not regenerate in adult mammals.
Second result: in mice with induced glaucoma (via increased intraocular pressure), OSK treatment restored visual function as measured by electroretinogram. Damaged ganglion cells recovered their ability to transmit visual signals.
Third result: in 12-month-old mice (approximate human equivalent of 50 years), OSK expression rejuvenated the DNA methylation profile of retinal cells, as measured by Horvath epigenetic clocks. The biological age of treated cells was significantly reduced compared to controls (PubMed).
The Lu et al. 2020 study demonstrated OSK efficacy in three distinct murine models: traumatic optic nerve injury, induced glaucoma, and natural retinal aging.
What made these results particularly remarkable is that OSK factors did not modify the DNA sequence. They reset epigenetic marks (DNA methylation and histone modifications, the proteins around which DNA wraps) toward a younger profile without altering differentiation genes. Retinal ganglion cells remained retinal ganglion cells. They simply functioned like younger cells.
The Mechanism of Partial Epigenetic Reprogramming
Cellular aging is accompanied by progressive epigenetic drift. DNA methylation profiles degrade: normally silent regions become accessible, normally active genes are repressed. Histone modifications (acetylation, methylation of H3 and H4 tails) become disorganized. The result is increasing transcriptional noise and a progressive loss of functional cellular identity.
The central hypothesis of partial reprogramming, formulated by Sinclair as the "information theory of aging," posits that the original epigenetic information is not destroyed. It is scrambled but recoverable. OSK factors would act as a reset mechanism that restores epigenetic marks toward their original configuration, akin to an error-correction software.
In practice, OCT4, SOX2, and KLF4 are "pioneer" transcription factors. They have the unique ability to access regions of DNA that are normally locked (compacted chromatin, or heterochromatin) and remodel them. During brief, controlled expression, they reorganize DNA methylation marks (chemical tags at CpG sites, the genome's control points) and modify histone profiles without fully activating the pluripotency program. The net result is measurable epigenetic rejuvenation by methylation clocks, with maintained tissue identity.
The distinction from complete reprogramming (iPSC) is fundamental. Complete reprogramming erases all epigenetic marks and returns the cell to an embryonic state. Partial reprogramming does not go that far. It corrects accumulated epigenetic noise without crossing the dedifferentiation threshold. The temporal control of factor expression is what separates rejuvenation from dedifferentiation.
ER-100: The Tet-On System Architecture
ER-100 translates these principles into a clinical product. The system relies on two AAV2 vectors administered via a single intravitreal injection.
The first vector carries a "molecular switch" (the rtTA transactivator) sensitive to doxycycline, a common oral antibiotic. The second vector contains the genes for OCT4, SOX2, and KLF4 under the control of an inducible promoter (TRE, Tetracycline Response Element), a DNA sequence that only activates in the presence of doxycycline. Without the drug, the system is silent. When the patient takes doxycycline, the switch engages and activates production of OSK factors.
This "tet-on" system confers a dual advantage. Activation is controllable: factor expression occurs only during the doxycycline administration window. Shutdown is reversible: once doxycycline is eliminated, expression ceases. In the clinical trial protocol, doxycycline is administered for 56 days (8 weeks) and then discontinued (source).
The choice of AAV2 is deliberate. This type of viral vector has a natural affinity for retinal cells, particularly retinal ganglion cells, which are precisely the cells damaged in glaucoma and ischemic optic neuropathy. Intravitreal injection (into the eye's transparent gel) confines the vector to the ocular space, a compartment relatively isolated from the immune system, reducing the risk of systemic immune response against the viral vector or the genes it carries.
The Phase 1 Trial: NCT07290244
The clinical trial registered as NCT07290244 is a Phase 1, open-label (no placebo) study designed to evaluate the safety and tolerability of a single dose of ER-100 (source).
The protocol plans to enroll 18 participants: 12 with open-angle glaucoma and 6 with non-arteritic anterior ischemic optic neuropathy (NAION). Inclusion criteria target adults aged 40-85 with moderate to advanced visual loss, intraocular pressure below 30 mmHg, and no need for glaucoma surgery within two months of injection.
Participants will be followed for 5 years total, with 9 visits during the first 6 months then one annual visit, totaling 14 clinical visits.
Primary endpoints are safety and tolerability: adverse events, immune responses, ophthalmologic parameters. Secondary endpoints include multiple visual assessments (visual acuity, visual field, electroretinogram). The 5-year follow-up reflects the appropriate regulatory caution for gene therapy: AAV vectors persist in transduced cells and their effects must be monitored over the long term.
Two elements of the design warrant attention. First, the absence of a placebo group. All participants will receive the active treatment. This is a common choice in Phase 1 for invasive therapies (intravitreal injection), but it means any visual improvement observed must be interpreted cautiously without a comparator. Second, the two selected indications — glaucoma and NAION — involve different pathophysiological mechanisms (progressive vs. acute ganglion cell loss), which will allow evaluation of partial reprogramming's potential in two distinct clinical contexts.
Preclinical Data in Non-Human Primates
Before the human trial, Life Biosciences presented non-human primate (NHP) data at the American Academy of Ophthalmology congress. These data are essential because the primate constitutes the most predictive model for human response in retinal pathologies (source).
The study used an induced NAION model in NHPs. ER-100 was administered via single intravitreal injection with daily systemic doxycycline. Immunohistochemistry (a tissue-staining technique that visualizes specific proteins) confirmed expression of all three transcription factors (OCT4, SOX2, KLF4) in cells located around the fovea (the retinal area responsible for central vision) in treated animals but not in vehicle controls.
Functionally, ER-100 significantly reduced deficits measured by pattern electroretinogram (pERG, which specifically assesses retinal ganglion cell function) and axon density. These results were observed in two paradigms: a prevention paradigm (treatment before injury) and a rescue paradigm (treatment after injury).
These primate data are the strongest to date for a partial epigenetic reprogramming therapy in an ocular disease model. However, they have not yet been published in a peer-reviewed journal, which limits independent evaluation.
Risks and Uncertainties
Caution demands clear identification of the risks associated with this approach.
Oncogenic risk remains the primary concern. While removing c-MYC from the cocktail considerably reduces this risk compared to OSKM, OCT4 and SOX2 are themselves involved in the biology of certain cancers. Uncontrolled expression of these factors can activate aberrant proliferation programs. The tet-on system provides a safeguard, but no inducible expression system is perfectly leak-proof. Low-level residual activation in the absence of doxycycline cannot be entirely excluded.
Mouse studies have shown that continuous OSKM factor expression causes rapid mortality from liver and intestinal failure due to massive cellular identity loss in these organs (PubMed). With ER-100, restriction to the ocular compartment and temporal control via doxycycline substantially mitigate this systemic risk. But any eventual extrapolation of this approach to other organs will need to confront this question head-on.
Durability of effect is unknown. Partial reprogramming resets epigenetic marks, but nothing prevents epigenetic drift from resuming after treatment cessation. Repeated treatments would raise the question of immune response against AAV capsids (the protein shells of the viral vectors), which generally intensifies after initial exposure.
Cost and accessibility represent a structural challenge. Approved gene therapies (Luxturna for Leber congenital amaurosis, Zolgensma for spinal muscular atrophy) fall in price ranges from $850,000 to $2.1 million per treatment. ER-100, should it ever gain approval, would likely be in a comparable order of magnitude.
The Competitive Landscape of Epigenetic Reprogramming
Life Biosciences is not alone in this field. Several major players are investing in cellular reprogramming as a strategy against aging.
Altos Labs, funded at $3 billion with backing from Jeff Bezos, has recruited some of the biggest names in the field (Shinya Yamanaka as senior scientific advisor, Juan Carlos Izpisua Belmonte). The company appointed a Chief Medical Officer (Joan Mannick) in 2025, signaling a transition toward clinical development. But as of March 2026, Altos Labs has not yet announced IND clearance.
Retro Biosciences, backed by Sam Altman (OpenAI), has raised significant funds and initiated a first human trial with RTR242, a cellular autophagy activator targeting Alzheimer's disease. Their hematopoietic stem cell reprogramming program remains at the preclinical stage.
Turn Biotechnologies is developing a distinct approach using transient messenger RNAs (ERA, Epigenetic Reprogramming of Aging) rather than AAV vectors. The theoretical advantage is the absence of genomic integration and finer temporal control, but clinical data are absent.
Life Biosciences' lead over these competitors is therefore clinical, not necessarily scientific. Having obtained the first IND clearance for a partial epigenetic reprogramming therapy confers a first-mover advantage but guarantees neither the efficacy nor the long-term superiority of the approach.
From the Eye to the Rest of the Body: An Uncertain Roadmap
The choice of the eye as the first target organ is strategically sound for both biological and regulatory reasons. The eye is an immunologically isolated compartment, reducing the risk of systemic immune reaction. The retina is accessible by direct injection. Functional measures (visual acuity, visual field, electroretinogram) are quantitative and standardized. And the targeted pathologies (glaucoma, NAION) represent unmet medical needs with well-characterized patient populations.
But the ultimate ambition of partial epigenetic reprogramming extends beyond ophthalmology. The question driving this field is whether epigenetic rejuvenation can be applied to the entire organism. The most provocative data on this point come from Macip et al. (2024), who showed that systemic administration of AAV9 carrying inducible OSK in 124-week-old mice extended median residual lifespan by 109% and improved several health parameters (PubMed).
These mouse results are striking, but translation to humans raises considerable difficulties. Systemic distribution of AAV vectors in humans has been associated with severe immune responses, including fatalities in gene therapy trials for other indications. Controlling OSK expression across dozens of different cell types, each with its own epigenetic landscape, is a challenge of a complexity that dwarfs treating a single cell type in an isolated organ.
The ER-100 trial is therefore a first step, not a destination. Its results will determine whether partial epigenetic reprogramming can safely cross the gap between animal models and humans. They will not answer the question of systemic generalization, which will require decades of further development.
What This Trial Means for Aging Science
The ER-100 clearance validates a hypothesis that seemed abstract a decade ago: cellular aging is not solely the product of irreversible DNA damage. It is also — perhaps primarily — an epigenetic phenomenon, and epigenetic marks are modifiable. If the Phase 1 trial demonstrates an acceptable safety profile, it will open the path to efficacy trials that directly test partial reprogramming's ability to restore tissue function in humans.
Results will not be immediate. The 5-year follow-up means complete data will not be available until 2031. Initial 6-month safety data could however be reported by late 2026 or early 2027, and will guide FDA decisions on potential expansion to non-ocular indications.
The stakes extend beyond Life Biosciences. A safety failure would chill the entire field of epigenetic reprogramming for years. A success would accelerate competing programs and attract massive funding toward this approach. In either case, the 18 participants in this trial carry on their retinas a significant share of the future of aging medicine.
Frequently asked questions
References
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76 (PubMed).
- Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129 (PubMed).
- Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115 (PubMed).
- Paine PT, Nguyen A, Ocampo A. Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology. Aging Cell. 2024;23(2):e14039 (PubMed).
- Pereira B, Correia FP, Alves IA, et al. Epigenetic reprogramming as a key to reverse ageing and increase longevity. Ageing Res Rev. 2024;95:102204 (PubMed).
- Macip CC, Hasan R, Hoznek V, et al. Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice. Cell Reprogram. 2024;26(1):24-32 (PubMed).
- Life Biosciences. FDA Clearance of IND Application for ER-100 in Optic Neuropathies. Press release, January 28, 2026 (source).
- Life Biosciences. Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function. AAO Presentation (source).
- ClinicalTrials.gov. Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy. NCT07290244 (source).
